Floatz logo

Trimethoprim

Infection

Radboud University Medical CenterSmall moleculePhase 4 / ApprovedDormant
A
81/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
71/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Infection cohort.

Asset / SponsorPhaseRating
SULFAMETHOXAZOLE
Radboud University Medical Center
Phase 4A
Ciprofloxacin
Radboud University Medical Center
Phase 4BBB
FILGRASTIM
Cellerant Therapeutics
Phase 3BB
Fosfomycin
Radboud University Medical Center
Phase 4BB
AMDINOCILLIN
Radboud University Medical Center
Phase 4BB

View all 50 →

Same molecule, other indications

Trimethoprim is also rated in:

methicillin-resistant staphylococcus aureus infectious diseaseDormant
BBB
Indicative ·
75 / 100
View asset →
MyelomaDormant
BB
Indicative ·
71 / 100
View asset →
PharmacokineticsDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →